Cochrane · systematic review · CD010628
Pharmacological interventions for somatoform disorders in adults
Kleinstäuber, M, Witthöft, M, Steffanowski, A, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
Common Mental DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
35
current version
GRADE rated
24
No studies
11
Included studies
NR
No studies 11 · 31.4%Ungraded 0 · 0%Very low 9 · 25.7%Low 15 · 42.9%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Tricyclic antidepressants versus placebo for somatoform disorders in adults
Population: somatoform disorders in adults
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Severity/intensity of MUPS (post‐treatment score on self report scales) Different self report scales (SCL‐90‐R Somatisation Subscore, VAS) Tricyclic antidepressants vs placebo | no estimate extracted | 2 studies · 239 participants | Low Downgraded: risk of bias, imprecision |
Acceptability (all‐cause drop‐outs) Tricyclic antidepressants vs placebo | no estimate extracted | NR | No studies |
Anxiety (post‐treatment score on self report and clinician‐rated scales) Tricyclic antidepressants vs placebo | no estimate extracted | NR | No studies |
Depression (post‐treatment score on self report and clinician‐rated scales) Tricyclic antidepressants vs placebo | no estimate extracted | NR | No studies |
Adverse effects (drop‐outs due to adverse effects) Tricyclic antidepressants vs placebo | no estimate extracted | NR | No studies |
Treatment response (post‐treatment score on self report and clinician‐rated scales) Tricyclic antidepressants vs placebo | no estimate extracted | NR | No studies |
Functional disability and quality of life (post‐treatment score on self report and clinician‐rated scales) Tricyclic antidepressants vs placebo | no estimate extracted | NR | No studies |
New‐generation antidepressants versus placebo for somatoform disorders in adults
Population: somatoform disorders in adults
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Severity/intensity of MUPS (post‐treatment score on self report scales) Different self report scales (PHQ‐15, MOSPM) New‐generation antidepressants vs placebo | no estimate extracted | 3 studies · 243 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Acceptability (all‐cause drop‐outs) New‐generation antidepressants vs placebo | RR 1.01 [0.64, 1.61] | 2 studies · 163 participants | Low Downgraded: risk of bias, imprecision |
Anxiety (post‐treatment score on self report and clinician‐rated scales) Clinician‐rated scales (HARS) New‐generation antidepressants vs placebo | no estimate extracted | 2 studies · 163 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Depression (post‐treatment score on self report and clinician‐rated scales) Different clinician‐rated scales (HDRS, MADRS) New‐generation antidepressants vs placebo | no estimate extracted | 2 studies · 163 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Adverse effects (drop‐outs due to adverse effects) New‐generation antidepressants vs placebo | RR 2.26 [0.52, 9.81] | 2 studies · 163 participants | Low Downgraded: risk of bias, imprecision |
Treatment response (post‐treatment score on self report and clinician‐rated scales) Different self report and clinician‐rated scales (PHQ‐15, CGI ‐ Improvement Scale) New‐generation antidepressants vs placebo | RR 2 [0.9, 4.43] | 2 studies · 163 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Functional disability and quality of life (post‐treatment score on self report scales) Different self report scales (SF‐36, SDS) New‐generation antidepressants vs placebo | no estimate extracted | 2 studies · 163 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Natural products versus placebo for somatoform disorders in adults
Population: somatoform disorders in adults
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Severity/intensity of MUPS (post‐treatment score on self report scales) Different self report scales (SOMS‐7, SCL‐90‐R Somatisation Subscore) Natural products vs placebo | no estimate extracted | 2 studies · 322 participants | Low Downgraded: risk of bias, imprecision |
Acceptability (all‐cause drop‐outs4) Natural products vs placebo | RR 0.85 [0.4, 1.78] | 3 studies · 506 participants | Low Downgraded: risk of bias, imprecision |
Anxiety (post‐treatment score on self report and clinician‐rated scales) Different self report and clinician‐rated scales (HARS, VAS) Natural products vs placebo | no estimate extracted | 2 studies · 321 participants | Low Downgraded: risk of bias, imprecision |
Depression (post‐treatment score on self report and clinician‐rated scales) Different self report and clinician‐rated scales (HDRS, BDI) Natural products vs placebo | no estimate extracted | 2 studies · 321 participants | Low Downgraded: risk of bias, imprecision |
Adverse effects (drop‐outs due to adverse effects4) Natural products vs placebo | RR 0.54 [0.08, 3.5] | 3 studies · 506 participants | Low Downgraded: risk of bias, imprecision |
Treatment response (post‐treatment score on self report and clinician‐rated scales) Different self report and clinician‐rated scales (PHQ‐15, CGI ‐ Improvement Scale) Natural products vs placebo | RR 1.77 [1.34, 2.34] | 2 studies · 324 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Functional disability and quality of life (post‐treatment score on self report scales) Natural products vs placebo | no estimate extracted | NR | No studies |
Tricyclic antidepressants versus another medication for somatoform disorders in adults
Population: somatoform disorders in adults
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Severity/intensity of MUPS (post‐treatment score on self report scales) Different self report scales (VAS‐Pain, SCL‐90‐R Somatisation Subscore) Tricyclic antidepressants vs another medication | no estimate extracted | 3 studies · 177 participants | Low Downgraded: risk of bias, imprecision |
Acceptability (all‐cause drop‐outs4) Tricyclic antidepressants vs another medication | RR 1.48 [0.59, 3.72] | 8 studies · 556 participants | Low Downgraded: risk of bias, imprecision |
Anxiety (post‐treatment score on self report and clinician‐rated scales) Different self report and clinician‐rated scales (HARS, SCL‐90 Anxiety Subscore) Tricyclic antidepressants vs another medication | no estimate extracted | 4 studies · 255 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Depression (post‐treatment score on self report and clinician‐rated scales) Different self report and clinician‐rated scales (VAS Sadness, HDRS, SCL‐90 Depression Subscore, ZDS) Tricyclic antidepressants vs another medication | no estimate extracted | 6 studies · 395 participants | Low Downgraded: risk of bias, imprecision |
Adverse effects (drop‐outs due to adverse effects4) Tricyclic antidepressants vs another medication | RR 2.37 [0.39, 14.28] | 8 studies · 556 participants | Low Downgraded: risk of bias, imprecision |
Treatment response (post‐treatment score on self report and clinician‐rated scales) CGI ‐ Improvement Scale Tricyclic antidepressants vs another medication | RR 0.93 [0.73, 1.19] | 2 studies · 130 participants | Low Downgraded: risk of bias, imprecision |
Functional disability and quality of life Tricyclic antidepressants vs another medication | no estimate extracted | NR | No studies |
Antidepressants versus a combination of medications for somatoform disorders in adults
Population: somatoform disorders in adults
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Severity/intensity of MUPS (post‐treatment score on self report scales) Different self report and clinician‐rated scales (SOMS‐7, SCL‐90 Somatisation Score) Antidepressants vs a combination of medications | no estimate extracted | 2 studies · 107 participants | Low Downgraded: risk of bias, imprecision |
Acceptability (all‐cause drop‐outs4) Antidepressants vs a combination of medications | RR 0.8 [0.25, 2.52] | 2 studies · 118 participants | Low Downgraded: risk of bias, imprecision |
Anxiety (post‐treatment score on self report and clinician‐rated scales) Different self report and clinician‐rated scales (HARS, SCL‐90 Anxiety Subscore) Antidepressants vs a combination of medications | no estimate extracted | 2 studies · 107 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Depression (post‐treatment score on self report and clinician‐rated scales) Different self report and clinician‐rated scales (HDRS, SCL‐90 depression subscore) Antidepressants vs a combination of medications | no estimate extracted | 2 studies · 107 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Adverse effects (drop‐outs due to adverse effects) Antidepressants vs a combination of medications | no estimate extracted | NR | No studies |
Treatment response (post‐treatment score on self report and clinician‐rated scales) Antidepressants vs a combination of medications | no estimate extracted | NR | No studies |
Functional disability and quality of life Antidepressants vs a combination of medications | no estimate extracted | NR | No studies |